---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-093920"
form_type: "8-K"
ticker: "DNTH"
cik: "0001690585"
company_name: "Dianthus Therapeutics, Inc. /DE/"
filed_at: "2024-08-08T23:59:59+00:00"
generated_at: "2026-05-31T11:02:57.430418+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Dianthus reports Q2 net loss $17.6M; cash $360.7M funds pipeline into 2H'27

## Summary
- Net loss $17.6M ($0.51/share) vs $11.1M ($12.73/share) in Q2 2023.
- Cash, equivalents & short-term investments $360.7M as of June 30, 2024, projected runway into 2H'27.
- Phase 2 MaGic trial in gMG ongoing; top-line results expected 2H'25.
- IND cleared for Phase 2 MoMeNtum trial in MMN; top-line results anticipated 2H'26.
- Alison Lawton appointed Chair of Board, effective July 1, 2024, succeeding Lonnie Moulder.

## SEC filing metadata
- accession: 0000950170-24-093920
- form_type: 8-K
- ticker: DNTH
- cik: 0001690585
- company_name: Dianthus Therapeutics, Inc. /DE/
- filed_at: 2024-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1690585/000095017024093920/0000950170-24-093920-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1690585/000095017024093920/dnth-20240808.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-093920
- JSON: https://secwatch.observer/filing/0000950170-24-093920.json
- Plain text: https://secwatch.observer/filing/0000950170-24-093920.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.